<html>

<head>
<meta http-equiv=Content-Type content="text/html; charset=us-ascii">
<meta name=Generator content="Microsoft Word 15 (filtered)">
<title>Orphacol S-33 - PI - clean</title>

<style>
<!--
 /* Font Definitions */
 @font-face
	{font-family:Helvetica;
	panose-1:2 11 6 4 2 2 2 2 2 4;}
@font-face
	{font-family:Wingdings;
	panose-1:5 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:SimSun;
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:"Cambria Math";
	panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
	{font-family:Verdana;
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"Arial Unicode MS";
	panose-1:2 11 6 4 2 2 2 2 2 4;}
@font-face
	{font-family:Tahoma;
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"\@SimSun";
	panose-1:2 1 6 0 3 1 1 1 1 1;}
 /* Style Definitions */
 p.MsoNormal, li.MsoNormal, div.MsoNormal
	{margin:0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
h1
	{margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:17.85pt;
	text-indent:-17.85pt;
	line-height:13.0pt;
	font-size:13.0pt;
	font-family:"Times New Roman",serif;
	text-transform:uppercase;
	font-weight:bold;}
h2
	{margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	line-height:13.0pt;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Helvetica",sans-serif;
	font-weight:bold;
	font-style:italic;}
h3
	{margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:4.0pt;
	margin-left:0in;
	line-height:13.0pt;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
h4
	{margin:0in;
	text-align:justify;
	line-height:13.0pt;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
h5
	{margin:0in;
	text-align:justify;
	line-height:13.0pt;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:normal;}
h6
	{margin:0in;
	line-height:13.0pt;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:normal;
	font-style:italic;}
p.MsoHeading7, li.MsoHeading7, div.MsoHeading7
	{margin:0in;
	text-align:justify;
	line-height:13.0pt;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-style:italic;}
p.MsoHeading8, li.MsoHeading8, div.MsoHeading8
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.35pt;
	text-align:justify;
	text-indent:-28.35pt;
	line-height:13.0pt;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;
	font-style:italic;}
p.MsoHeading9, li.MsoHeading9, div.MsoHeading9
	{margin:0in;
	text-align:justify;
	line-height:13.0pt;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;
	font-style:italic;}
p.MsoCommentText, li.MsoCommentText, div.MsoCommentText
	{mso-style-link:"Commentaire Car";
	margin:0in;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.MsoHeader, li.MsoHeader, div.MsoHeader
	{margin:0in;
	font-size:10.0pt;
	font-family:"Helvetica",sans-serif;}
p.MsoFooter, li.MsoFooter, div.MsoFooter
	{margin:0in;
	font-size:8.0pt;
	font-family:"Helvetica",sans-serif;}
p.MsoBodyText, li.MsoBodyText, div.MsoBodyText
	{margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:green;
	font-style:italic;}
p.MsoBodyTextIndent, li.MsoBodyTextIndent, div.MsoBodyTextIndent
	{mso-style-link:"Retrait corps de texte Car";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	text-align:justify;
	text-autospace:none;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyTextFirstIndent2, li.MsoBodyTextFirstIndent2, div.MsoBodyTextFirstIndent2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:14.15pt;
	text-indent:10.5pt;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;}
p.MsoBodyText2, li.MsoBodyText2, div.MsoBodyText2
	{margin:0in;
	text-align:justify;
	line-height:13.0pt;
	text-autospace:none;
	border:none;
	padding:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:blue;
	font-weight:bold;
	text-decoration:underline;}
p.MsoBodyText3, li.MsoBodyText3, div.MsoBodyText3
	{margin:0in;
	text-align:justify;
	text-autospace:none;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:blue;}
p.MsoBodyTextIndent2, li.MsoBodyTextIndent2, div.MsoBodyTextIndent2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:56.7pt;
	text-align:justify;
	line-height:13.0pt;
	text-autospace:none;
	border:none;
	padding:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:blue;
	font-weight:bold;}
p.MsoBodyTextIndent3, li.MsoBodyTextIndent3, div.MsoBodyTextIndent3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:31.65pt;
	text-align:justify;
	line-height:13.0pt;
	text-autospace:none;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
a:link, span.MsoHyperlink
	{color:blue;
	text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
	{color:purple;
	text-decoration:underline;}
p.MsoDocumentMap, li.MsoDocumentMap, div.MsoDocumentMap
	{margin:0in;
	line-height:13.0pt;
	background:navy;
	font-size:11.0pt;
	font-family:"Tahoma",sans-serif;}
p
	{margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Arial Unicode MS",serif;}
p.MsoCommentSubject, li.MsoCommentSubject, div.MsoCommentSubject
	{margin:0in;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.MsoAcetate, li.MsoAcetate, div.MsoAcetate
	{margin:0in;
	line-height:13.0pt;
	font-size:8.0pt;
	font-family:"Tahoma",sans-serif;}
p.MsoRMPane, li.MsoRMPane, div.MsoRMPane
	{margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.EMEAEnBodyText, li.EMEAEnBodyText, div.EMEAEnBodyText
	{mso-style-name:"EMEA En Body Text";
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	text-align:justify;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.AHeader1, li.AHeader1, div.AHeader1
	{mso-style-name:"AHeader 1";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:14.2pt;
	text-indent:-14.2pt;
	font-size:12.0pt;
	font-family:"Arial",sans-serif;
	font-weight:bold;}
p.AHeader2, li.AHeader2, div.AHeader2
	{mso-style-name:"AHeader 2";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:35.45pt;
	text-indent:-21.25pt;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;
	font-weight:bold;}
p.AHeader3, li.AHeader3, div.AHeader3
	{mso-style-name:"AHeader 3";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:63.8pt;
	text-indent:-28.35pt;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;
	font-weight:bold;}
p.AHeader2abc, li.AHeader2abc, div.AHeader2abc
	{mso-style-name:"AHeader 2 abc";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:63.8pt;
	text-align:justify;
	text-indent:-28.35pt;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;}
p.AHeader3abc, li.AHeader3abc, div.AHeader3abc
	{mso-style-name:"AHeader 3 abc";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:85.05pt;
	text-align:justify;
	text-indent:-21.25pt;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;}
p.Revision1, li.Revision1, div.Revision1
	{mso-style-name:Revision1;
	margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.Default, li.Default, div.Default
	{mso-style-name:Default;
	mso-style-link:"Default Char1";
	margin:0in;
	text-indent:0in;
	text-autospace:none;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
span.DefaultChar1
	{mso-style-name:"Default Char1";
	mso-style-link:Default;
	color:black;}
p.BodyTextCTD, li.BodyTextCTD, div.BodyTextCTD
	{mso-style-name:"Body Text CTD";
	mso-style-link:"Body Text CTD Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	text-align:justify;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
span.BodyTextCTDChar
	{mso-style-name:"Body Text CTD Char";
	mso-style-link:"Body Text CTD";}
span.CommentaireCar
	{mso-style-name:"Commentaire Car";
	mso-style-link:Commentaire;}
span.RetraitcorpsdetexteCar
	{mso-style-name:"Retrait corps de texte Car";
	mso-style-link:"Retrait corps de texte";}
span.BodyTextFirstIndent2Char
	{mso-style-name:"Body Text First Indent 2 Char";
	mso-style-link:"Retrait corps et 1re lig\.";}
p.BodytextAgency, li.BodytextAgency, div.BodytextAgency
	{mso-style-name:"Body text \(Agency\)";
	mso-style-link:"Body text \(Agency\) Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:7.0pt;
	margin-left:0in;
	line-height:14.0pt;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;}
span.BodytextAgencyChar
	{mso-style-name:"Body text \(Agency\) Char";
	mso-style-link:"Body text \(Agency\)";
	font-family:"Verdana",sans-serif;}
 /* Page Definitions */
 @page WordSection1
	{size:8.5in 11.0in;
	margin:56.7pt 70.9pt 56.7pt 70.9pt;}
div.WordSection1
	{page:WordSection1;}
 /* List Definitions */
 ol
	{margin-bottom:0in;}
ul
	{margin-bottom:0in;}
-->
</style>

</head>

<body lang=EN-US link=blue vlink=purple style='word-wrap:break-word'>

<div class=WordSection1>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB
style='color:green'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></i></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>ANNEX I</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>SUMMARY OF PRODUCT CHARACTERISTICS</span></b></p>

<i><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:green'><br clear=all style='page-break-before:always'>
</span></i>

<p class=MsoNormal><span lang=EN-GB><img width=21 height=18
src="Orphacol%20S-33%20-%20PI%20-%20clea_files/image003.gif"></span><span
lang=EN-GB>This medicinal product is subject to additional monitoring. This
will allow quick identification of new safety information. Healthcare
professionals are asked to report any suspected adverse reactions. See section
4.8 for how to report adverse reactions.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME
OF THE MEDICINAL PRODUCT</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify;line-height:normal;text-autospace:
none'><span lang=FR>Orphacol 50&nbsp;mg hard capsules</span></p>

<p class=MsoNormal style='text-align:justify;line-height:normal;text-autospace:
none'><span lang=FR>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=FR>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=FR>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; QUALITATIVE
AND QUANTITATIVE COMPOSITION</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=FR>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Each hard
capsule contains 50&nbsp;mg of cholic acid.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAEnBodyText style='margin:0in;text-autospace:none'><u><span
lang=EN-GB>Excipient(s) with known effect</span></u><span lang=EN-GB>:</span>
Lactose monohydrate (145.79&nbsp;mg per capsule).</p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>For the full
list of excipients, see section&nbsp;6.1.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACEUTICAL
<span style='text-transform:uppercase'>form</span></span></b></p>

<p class=MsoNormal style='text-align:justify;line-height:normal;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify;line-height:normal;text-autospace:
none'><span lang=EN-GB>Hard capsule (capsule).</span></p>

<p class=MsoNormal style='text-align:justify;line-height:normal;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify;line-height:normal;text-autospace:
none'><span lang=EN-GB>Oblong, opaque, blue and white capsule.</span></p>

<p class=MsoNormal style='text-align:justify;line-height:normal;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB style='text-transform:uppercase'>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Clinical
particulars</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>4.1&nbsp;&nbsp;&nbsp;&nbsp; Therapeutic indications</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Orphacol is
indicated for the treatment of inborn errors in primary bile acid synthesis due
to 3&#946;&#8209;Hydroxy&#8209;&#916;<sup>5</sup>&#8209;C<sub>27</sub>&#8209;steroid
oxidoreductase deficiency or &#916;<sup>4</sup>&#8209;3&#8209;Oxosteroid&#8209;5&#946;&#8209;reductase
deficiency in infants, children and adolescents aged 1&nbsp;month to
18&nbsp;years and adults.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.5pt;text-indent:-28.5pt;line-height:
normal'><b><span lang=EN-GB>4.2<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></b><b><span lang=EN-GB>Posology and method of administration</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Treatment must
be initiated and monitored by an experienced gastroenterologist/hepatologist or
a paediatric gastroenterologist/hepatologist in the case of paediatric
patients.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Default><span style='font-size:11.0pt'>In case of persistent lack of
therapeutic response to cholic acid monotherapy, other treatment options should
be considered (see section 4.4). Patients should be monitored as follows: 3-monthly
during the first year, 6&#8209;monthly during the subsequent three years and
annually thereafter (see below).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Posology</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The dose must be
adjusted for each patient in a specialised unit according to blood and/or urine
chromatographic bile acid profiles. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>3&#946;&#8209;Hydroxy&#8209;&#916;<sup>5</sup>&#8209;C<sub>27</sub>&#8209;steroid
oxidoreductase deficiency</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The daily dose
ranges from 5 to 15&nbsp;mg/kg in infants, children, adolescents and adults. In
all age groups, the minimum dose is 50&nbsp;mg and the dose is adjusted in
50&nbsp;mg steps. In adults, the daily dose should not exceed 500&nbsp;mg.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&#916;<sup>4</sup>&#8209;3&#8209;Oxosteroid&#8209;5&#946;&#8209;reductase
deficiency </span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The daily dose
ranges from 5 to 15&nbsp;mg/kg in infants, children, adolescents and adults. In
all age groups, the minimum dose is 50&nbsp;mg and the dose is adjusted in
50&nbsp;mg steps. In adults, the daily dose should not exceed 500&nbsp;mg.&nbsp;
</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The daily dose
may be divided if it consists of more than one capsule in order to mimic the
continuous production of cholic acid in the body and to reduce the number of
capsules that need to be taken per administration. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>During the
initiation of therapy and dose adjustment, serum and/or urine bile acid levels
should be monitored intensively (at least every three months during the first
year of treatment, every six months during the second year) using </span><span
lang=EN-GB>suitable analytical techniques</span><span lang=EN-GB>. The
concentrations of the abnormal bile acid metabolites synthesised in 3&#946;&#8209;Hydroxy&#8209;&#916;<sup>5</sup>&#8209;C<sub>27</sub>&#8209;steroid
oxidoreductase deficiency (3&#946;,&nbsp;7&#945;&#8209;dihydroxy- and
3&#946;,&nbsp;7&#945;,&nbsp;12&#945;&#8209;trihydroxy&#8209;5&#8209;cholenoic
acids) or in &#916;<sup>4</sup>&#8209;3&#8209;Oxosteroid&#8209;5&#946;&#8209;reductase
deficiency (3&#8209;oxo&#8209;7&#945;&#8209;hydroxy- and 3&#8209;oxo&#8209;7&#945;,&nbsp;12&#945;&#8209;dihydroxy&#8209;4&#8209;cholenoic
acids) should be determined. At each investigation, the need for dose
adjustment should be considered. The lowest dose of cholic acid that
effectively reduces the bile acid metabolites to as close to zero as possible
should be chosen. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Patients that
have previously been treated with other bile acids or other cholic acid
preparations should be closely monitored in the same manner during the
initiation of treatment with Orphacol. The dose should be adjusted accordingly,
as described above. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Liver parameters
should also be monitored, preferentially more frequently than serum and/or
urine bile acid levels. Concurrent elevation of serum gamma glutamyltransferase
(GGT), alanine aminotransferase (ALT) and/or serum bile acids above normal
levels may indicate overdose. Transient elevations of transaminases at the
initiation of cholic acid treatment have been observed and do not indicate the
need for a dose reduction if GGT is not elevated and if serum bile acid levels
are falling or in the normal range.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>After the
initiation period, serum and/or urine bile acids (using </span><span
lang=EN-GB>suitable analytical techniques</span><span lang=EN-GB>) and liver
parameters should be determined annually, at a minimum, and the dose adjusted
accordingly. Additional or more frequent investigations should be undertaken to
monitor therapy during periods of fast growth, concomitant disease and
pregnancy (see section&nbsp;4.6).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Special
populations</span></u></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>Elderly
population (&#8805;65&nbsp;years old) </span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>There is no
experience in elderly patients. The dose of cholic acid should be adjusted
individually.</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>Renal
impairment </span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>No data are
available for patients with renal impairment. The dose of cholic acid should be
adjusted individually.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>Hepatic
impairment </span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Limited data are
available for patients with minor to severe hepatic impairment related to
3&#946;&#8209;Hydroxy&#8209;&#916;<sup>5</sup>&#8209;C<sub>27</sub>&#8209;steroid
oxidoreductase deficiency or &#916;<sup>4</sup>&#8209;3&#8209;Oxosteroid&#8209;5&#946;&#8209;reductase
deficiency. Patients are expected to present with some degree of hepatic
impairment at diagnosis, which improves under cholic acid therapy. The dose of
cholic acid should be adjusted individually.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>No experience
exists in patients with hepatic impairment from causes other than
3&#946;-Hydroxy&#8209;&#916;<sup>5</sup>&#8209;C<sub>27</sub>&#8209;steroid
oxidoreductase deficiency or &#916;<sup>4</sup>&#8209;3&#8209;Oxosteroid&#8209;5&#946;&#8209;reductase
deficiency and no dose recommendation can be given. Patients with hepatic
impairment should be monitored closely (see section 4.4).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>Familial
hypertriglyceridemia</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Patients with
newly diagnosed or a family history of familial hypertriglyceridemia are
expected to poorly absorb cholic acid in the intestine. The cholic acid dose
for patients with familial hypertriglyceridemia will have to be established and
adjusted as described, but an elevated dose, notably higher than the
500&nbsp;mg daily limit for adult patients, may be required and safe.</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>Paediatric
population</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Cholic acid
therapy has been used for infants from one month of age, and for children and
adolescents. The dose recommendations reflect the use in this population. The
daily dose in infants from 1&nbsp;month to 2&nbsp;years of age, children and
adolescents ranges from 5 to 15&nbsp;mg/kg and must be adjusted individually
for each patient.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Method of administration</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Orphacol
capsules must be taken with food at approximately the same time each day, in
the morning and/or evening. Administration with food may increase cholic acid
bioavailability and improve tolerability. Regular and fixed times of administration
support the patient&#8217;s or caregiver&#8217;s compliance. Capsules</span><span
lang=EN-GB> </span><span lang=EN-GB>must be swallowed whole with water, without
chewing.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>For infants and
children who cannot swallow capsules, the capsules may be opened and the
content added to infant formula or juice. For additional information, see
section 6.6.</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>4.3&nbsp;&nbsp;&nbsp;&nbsp; Contraindications</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Hypersensitivity
to the active substance or to any of the excipients listed in section 6.1.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Concomitant use
of phenobarbital with cholic acid (see section 4.5).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>4.4&nbsp;&nbsp;&nbsp;&nbsp; Special warnings and
precautions for use</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Cases of severe
hepatotoxicity, including cases with fatal outcome, have been reported, with
the use of cholic acid. Treatment with cholic acid in patients with
pre-existing hepatic impairment should be given under close monitoring and, for
all patients, should be stopped if abnormal hepatocellular function, as
measured by prothrombin time, does not improve within 3&nbsp;months of the
initiation of cholic acid treatment. A concomitant decrease of urine total bile
acids should be observed. Treatment should be stopped earlier if there are
clear indicators of severe hepatic failure.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u>Familial hypertriglyceridemia</u></p>

<p class=MsoNormal style='line-height:normal'>Patients with newly diagnosed or
a family history of familial hypertriglyceridaemia may have poor absorption of
cholic acid from the intestine. The dose of cholic acid in such patients should
be established and adjusted as described, but an elevated dose, notably higher
than the 500&nbsp;mg daily limit for adult patients, may be required. </p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=FR>Excipients</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=FR>Orphacol capsules
contain lactose. </span><span lang=EN-GB>Patients with rare hereditary problems
of galactose intolerance, total lactase deficiency or glucose-galactose
malabsorption should not take this medicinal product.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>4.5&nbsp;&nbsp;&nbsp;&nbsp; Interaction with other
medicinal products and other forms of interaction</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Phenobarbital
antagonises the effect of cholic acid. Use of phenobarbital in patients with
3&#946;&#8209;Hydroxy&#8209;&#916;<sup>5</sup>&#8209;C<sub>27</sub>&#8209;steroid
oxidoreductase deficiency or &#916;<sup>4</sup>&#8209;3&#8209;Oxosteroid&#8209;5&#946;&#8209;reductase
deficiency treated with cholic acid is contraindicated (see section 4.3).
Alternative treatments should be used.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Ciclosporin
alters the pharmacokinetics of cholic acid by inhibition of the hepatic uptake
and hepatobiliary secretion of bile acids, as well as its pharmacodynamics by
inhibition of cholesterol 7&#945;&#8209;hydroxylase. Co-administration should
be avoided. If administration of ciclosporin is considered necessary, serum and
urine bile acid levels should be closely monitored and the cholic acid dose
adjusted accordingly.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Bile acid
sequestrants (cholestyramine, colestipol, colesevelam) and certain antacids (e.g.
aluminium hydroxide) bind bile acids and lead to their elimination.
Administration of these medicinal products is expected to reduce the effect of
cholic acid. The dose of bile acid sequestrants or antacids must be separated
from the dose of cholic acid by an interval of 5&nbsp;hours, regardless of
which medicinal product is administered first.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The effect of
food on the bioavailability of cholic acid has not been studied.</span><span
lang=EN-GB> </span><span lang=EN-GB>There is a theoretical possibility that a</span><span
lang=EN-GB>dministration with food may increase cholic acid bioavailability and
improve tolerability.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>4.6&nbsp;&nbsp;&nbsp;&nbsp; </span></b><b><span
lang=EN-GB>Fertility, p</span></b><b><span lang=EN-GB>regnancy and lactation</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Women of
childbearing potential</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>There is no need
for contraceptive measures in women of childbearing potential treated with
cholic acid or their partners. Women of childbearing potential should conduct a
pregnancy test as soon as a pregnancy is suspected.</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Pregnancy</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>There is a
limited amount of data (less than 20 pregnancy outcomes) from the use of cholic
acid in pregnant women. The exposed pregnancies showed no adverse reactions to
cholic acid and resulted in normal, healthy children. Animal studies do not
indicate direct or indirect harmful effects with respect to reproductive
toxicity (see section&nbsp;5.3). </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>It is extremely
important that pregnant women continue their therapy during pregnancy.</span><span
lang=EN-GB> As a precautionary measure, pregnant women and their unborn
children should be closely monitored. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Breastfeeding</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Cholic acid and
its metabolites are excreted in human milk, but at therapeutic doses of
Orphacol, no effects on the breastfed newborns/infants are anticipated.
Orphacol can be used during breast-feeding.</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Fertility</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>No data on the
effects of cholic acid on fertility are available. At therapeutic doses, no
effect on fertility is anticipated.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>4.7&nbsp;&nbsp;&nbsp;&nbsp; Effects on ability to
drive and use machines</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Cholic acid has
no or negligible influence on the ability to drive and use machines.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.5pt;text-indent:-28.5pt;line-height:
normal'><b><span lang=EN-GB>4.8<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></b><b><span lang=EN-GB>Undesirable effects</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Summary of
the safety profile</span></u><i><span lang=EN-GB> </span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Due to the
rarity of the diseases, the information about the most serious and/or most
frequently occurring adverse reactions is limited. Diarrhoea, increased
transaminases and pruritus have been associated with overdosage and disappeared
after dose reduction. Development of gallstones associated with long-term
treatment have been reported in very limited number of patients.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Tabulated
list of adverse reactions</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The following
table lists adverse reactions reported in the literature under treatment with
cholic acid. The frequency of these reactions is not known (cannot be estimated
from the available data).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="100%"
 style='width:100.0%;border-collapse:collapse;border:none'>
 <tr>
  <td width="50%" valign=top style='width:50.0%;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>MedDRA
  System Organ Class</span></b></p>
  </td>
  <td width="50%" valign=top style='width:50.0%;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Adverse
  reaction</span></b></p>
  </td>
 </tr>
 <tr>
  <td width="50%" valign=top style='width:50.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Gastrointestinal
  disorders</span></p>
  </td>
  <td width="50%" valign=top style='width:50.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Diarrhoea</span></p>
  </td>
 </tr>
 <tr>
  <td width="50%" valign=top style='width:50.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Hepatobiliary
  disorders</span></p>
  </td>
  <td width="50%" valign=top style='width:50.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Transaminases
  increased</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Gallstones</span></p>
  </td>
 </tr>
 <tr>
  <td width="50%" valign=top style='width:50.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Skin and
  subcutaneous tissue disorders</span></p>
  </td>
  <td width="50%" valign=top style='width:50.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Pruritus </span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Description
of selected adverse reactions</span></u></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>The development
of pruritus and/or diarrhoea has been observed during treatment with Orphacol.
These reactions abated after dose reduction and are suggestive of overdose.
Patients presenting with pruritus and/or persistent diarrhoea should be
investigated for a potential overdose by a serum and/or urine bile acid assay
(see section 4.9).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Gallstones have
been reported after long-term therapy.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Paediatric
population </span></u><span lang=EN-GB>The presented safety information is
derived principally from paediatric patients. The available literature is not
sufficient to detect a difference in the safety of cholic acid within
paediatric age groups or between paediatric patients and adults.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Other special
populations</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Please refer to
section 4.2 for use of Orphacol in special populations.</span></p>

<p class=MsoNormal style='text-align:justify;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><u><span lang=EN-GB>Reporting of
suspected adverse reactions</span></u></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Reporting
suspected adverse reactions after authorisation of the medicinal product is
important. It allows continued monitoring of the benefit/risk balance of the
medicinal product. Healthcare professionals are asked to report any suspected
adverse reactions via <span style='background:silver'>the national reporting
system listed in <a
href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc">Appendix
V</a></span>.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>4.9&nbsp;&nbsp;&nbsp;&nbsp; Overdose</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Episodes of
symptomatic overdose have been reported, including accidental overdose.
Clinical features were limited to pruritus and diarrhoea. Laboratory tests
showed elevation of serum gamma glutamyltransferase (GGT) transaminases and
serum bile acid concentrations. Reduction of the dose led to resolution of the
clinical signs and correction of abnormal laboratory parameters.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In the case of
an accidental overdose, treatment should be continued at the recommended dose
after normalisation of clinical signs and/or biological abnormalities.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACOLOGICAL
PROPERTIES</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>5.1 &nbsp;&nbsp;&nbsp; Pharmacodynamic properties</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Pharmacotherapeutic
group: Bile and liver therapy, bile acid and derivatives, ATC code: A05AA03 </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Cholic acid is
the predominant primary bile acid in man. In patients with </span><span
lang=EN-GB>inborn deficiency of 3&#946;&#8209;Hydroxy&#8209;&#916;<sup>5</sup>&#8209;C<sub>27</sub>&#8209;steroid
oxidoreductase and &#916;<sup>4</sup>&#8209;3&#8209;Oxosteroid&#8209;5&#946;&#8209;reductase,
the biosynthesis of primary bile acids is reduced or absent. Both inborn
diseases are extremely rare, with a prevalence in Europe of about 3 to 5
patients with 3&#946;&#8209;Hydroxy&#8209;&#916;<sup>5</sup>&#8209;C<sub>27</sub>&#8209;steroid
oxidoreductase deficiency per 10 million inhabitants, and an estimated ten-fold
lower prevalence for &#916;<sup>4</sup>&#8209;3&#8209;Oxosteroid&#8209;5&#946;&#8209;reductase
deficiency. In the absence of treatment, unphysiologic cholestatic and
hepatotoxic bile acid metabolites are predominant in the liver, serum and
urine. The rational basis for treatment consists of restoration of the bile
acid-dependent component of bile flow enabling restoration of biliary secretion
and biliary elimination of toxic metabolites; inhibition of the production of
the toxic bile acid metabolites by negative feedback on cholesterol 7&#945;&#8209;hydroxylase,
which is the rate-limiting enzyme in bile acid synthesis; and improvement of
the patient&#8217;s nutritional status by correcting intestinal malabsorption
of fats and fat-soluble vitamins.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Clinical
experience has been reported in the literature from small cohorts of patients
and single case reports; absolute patient numbers are small due to the rarity
of the conditions. This rarity also made the conduct of controlled clinical
studies impossible. Overall, cholic acid treatment results for about 60
patients with 3&#946;&#8209;Hydroxy&#8209;&#916;<sup>5</sup>&#8209;C<sub>27</sub>&#8209;steroid
oxidoreductase deficiency are reported in the literature. Detailed long-term data
on treatment with cholic acid monotherapy are available for 14 patients observed
for up to 12.9 years. Cholic acid treatment results for seven patients with &#916;<sup>4</sup>&#8209;3&#8209;Oxosteroid&#8209;5&#946;&#8209;reductase
deficiency for up to 14 years are reported in the literature. Detailed medium-
to long-term data are available for 5 of these patients, of whom 1 has been
treated with cholic acid monotherapy. Oral cholic acid therapy has been shown
to: postpone or obviate the need for liver transplantation; restore normal
laboratory parameters; improve histological lesions of the liver, and significantly
improve all of the patient&#8217;s symptoms. Mass spectrometry analysis of
urine during cholic acid therapy shows the presence of cholic acid and a marked
reduction, or even complete elimination of the toxic bile acid metabolites.
This reflects restoration of an effective feedback control of bile acid
synthesis and a metabolic equilibrium. In addition, blood cholic acid
concentration was normal and fat-soluble vitamins were restored to their normal
range.</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Paediatric
population</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The clinical
experience reported in the literature is from a patient population with inborn
deficiency of 3&#946;&#8209;Hydroxy&#8209;&#916;<sup>5</sup>&#8209;C<sub>27</sub>&#8209;steroid
oxidoreductase or &#916;<sup>4</sup>&#8209;3&#8209;Oxosteroid&#8209;5&#946;&#8209;reductase
that includes principally infants from the age of one month, children and
adolescents. However, absolute numbers of cases are small.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>This medicinal
product has been authorised under &#8220;Exceptional Circumstances&#8221;.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>This means that
due to the rarity of the disease and for ethical reasons it has not been
possible to obtain complete information on this medicinal product.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The European
Medicines Agency will review any new information which may become available
every year and this SmPC will be updated as necessary.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>5.2&nbsp;&nbsp;&nbsp;&nbsp; Pharmacokinetic
properties</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Cholic acid, a primary bile acid, is partially absorbed in the
ileum. The remaining part is transformed by reduction of the 7&#945;&#8209;hydroxy
group to deoxycholic acid (3&#945;,&nbsp;12&#945;&#8209;dihydroxy) by
intestinal bacteria. Deoxycholic acid is a secondary bile acid. More than 90%
of the primary and secondary bile acids are reabsorbed in the ileum by a
specific active transporter and are recycled to the liver by the portal vein;
the remainder is excreted in the faeces. A small fraction of bile acids is
excreted in urine.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>No
pharmacokinetic study data for Orphacol are available. </span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>5.3&nbsp;&nbsp;&nbsp;&nbsp; Preclinical safety data</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The available
non-clinical data in the literature reveal no special hazard for humans based
on studies of safety pharmacology, repeated dose toxicity, genotoxicity,
carcinogenic potential and toxicity to reproduction. The studies have however
not been conducted to the same level of detail as for a pharmaceutical agent,
as cholic acid is a physiological substance in animals and humans.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The intravenous
LD<sub>50</sub> of cholic acid in mice is 350&nbsp;mg/kg body weight.
Parenteral administration may cause haemolysis and cardiac arrest. Administered
orally, bile acids and salts generally have only a minor toxic potential. The
oral LD<sub>50</sub> in mice is 1520&nbsp;mg/kg. In repeated-dose studies,
frequently reported effects of cholic acid have included decreased body weight,
diarrhoea and liver damage with elevated transaminases. Increased liver weight
and gallstones have been reported in repeated dose studies in which cholic acid
was co-administered with cholesterol. </span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Cholic acid
showed non-significant mutagenic activity in a battery of genotoxicity tests
performed <i>in vitro</i>. Animal studies showed that cholic acid did not
induce any teratogenic effect or foetal toxicity.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACEUTICAL
PARTICULARS</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>6.1&nbsp;&nbsp;&nbsp;&nbsp; List of excipients</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Capsule content:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lactose
monohydrate, </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Colloidal
anhydrous silica,</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Magnesium
stearate.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Capsule shell:</span></p>

<p class=MsoNormal style='line-height:normal'>Gelatin (bovine origin),</p>

<p class=MsoNormal style='line-height:normal'><span lang=IT>Titanium dioxide
(E171),</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=IT>Carmine blue
(E132).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=IT>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>6.2&nbsp;&nbsp;&nbsp;&nbsp; Incompatibilities</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Not applicable.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>6.3&nbsp;&nbsp;&nbsp;&nbsp; Shelf life</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>3&nbsp;years</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>6.4&nbsp;&nbsp;&nbsp;&nbsp; Special precautions for
storage</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Store below
30&deg;C.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.5pt;text-indent:-28.5pt;line-height:
normal'><b><span lang=EN-GB>6.5<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></b><b><span lang=EN-GB>Nature and contents of container</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>PVC</span><span
lang=BG>/</span><span lang=EN-GB>PVDC</span><span lang=EN-GB>-aluminium blister
of 10&nbsp;capsules.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Pack sizes: 30,
60, 120. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Not all pack
sizes may be marketed.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><a name="OLE_LINK1"><b><span lang=EN-GB>6.6&nbsp;&nbsp;&nbsp;&nbsp; Special
precautions for disposal and other handling</span></b></a></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Use in the
paediatric population</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>See also
section&nbsp;4.2. For infants and children who cannot swallow capsules, the
capsules may be opened and the content added to infant formula or
infant-adapted apple/orange or apple/apricot juice. Other food such as fruit
compote or yoghurt may be suitable for administration, but no data on the
compatibility or palatability</span><b><i><span lang=EN-GB style='font-size:
12.0pt'> </span></i></b><span lang=EN-GB>are available.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Any unused
product or waste material should be disposed of in accordance with local
requirements.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=FR-CH>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; MARKETING
AUTHORISATION HOLDER</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=FR-CH>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=FR>Laboratoires CTRS</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=FR>63, rue de
l&#8217;Est</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=FR>92100
Boulogne-Billancourt</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=FR>France</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=FR>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=FR>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=FR>8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; MARKETING AUTHORISATION
NUMBER(S) </span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=FR>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=FR>EU/1/13/870/001</span><span
lang=FR> </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=FR>EU/1/13/870/002</span><span
lang=FR> </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EU/1/13/870/003</span><span
lang=EN-GB> </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; DATE OF
FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Date of first
authorisation: 12 September 2013</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Date of latest
renewal: 24 April 2019</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>10.&nbsp;&nbsp;&nbsp;&nbsp; DATE OF REVISION OF THE
TEXT</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Detailed information on this medicinal product </span><span
lang=EN-GB>is available on the website of the European Medicines Agency <span
style='color:blue'><a href="http://www.ema.europa.eu/">http://www.ema.europa.eu</a></span></span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal><span lang=EN-GB><img border=0 width=21 height=18
src="Orphacol%20S-33%20-%20PI%20-%20clea_files/image003.gif"></span><span
lang=EN-GB>This medicinal product is subject to additional monitoring. This
will allow quick identification of new safety information. Healthcare
professionals are asked to report any suspected adverse reactions. See section
4.8 for how to report adverse reactions.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME
OF THE MEDICINAL PRODUCT</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify;line-height:normal;text-autospace:
none'><span lang=FR>Orphacol 250&nbsp;mg hard capsules</span></p>

<p class=MsoNormal style='text-align:justify;line-height:normal;text-autospace:
none'><span lang=FR>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=FR>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=FR>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; QUALITATIVE
AND QUANTITATIVE COMPOSITION</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=FR>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Each hard
capsule contains 250&nbsp;mg of cholic acid.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAEnBodyText style='margin:0in;text-autospace:none'><u><span
lang=EN-GB>Excipient(s)</span><span lang=EN-GB> </span></u><u><span lang=EN-GB>with
known effect</span></u><span lang=EN-GB>:</span> Lactose monohydrate (66.98&nbsp;mg
per capsule).</p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>For the full
list of excipients, see section&nbsp;6.1.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACEUTICAL
<span style='text-transform:uppercase'>form</span></span></b></p>

<p class=MsoNormal style='text-align:justify;line-height:normal;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify;line-height:normal;text-autospace:
none'><span lang=EN-GB>Hard capsule(capsule).</span></p>

<p class=MsoNormal style='text-align:justify;line-height:normal;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify;line-height:normal;text-autospace:
none'><span lang=EN-GB>Oblong, opaque, green and white capsule.</span></p>

<p class=MsoNormal style='text-align:justify;line-height:normal;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB style='text-transform:uppercase'>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Clinical
particulars</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>4.1&nbsp;&nbsp;&nbsp;&nbsp; Therapeutic indications</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Orphacol is
indicated for the treatment of inborn errors in primary bile acid synthesis due
to 3&#946;&#8209;Hydroxy&#8209;&#916;<sup>5</sup>&#8209;C<sub>27</sub>&#8209;steroid
oxidoreductase deficiency or &#916;<sup>4</sup>&#8209;3&#8209;Oxosteroid&#8209;5&#946;&#8209;reductase
deficiency in infants, children and adolescents aged 1&nbsp;month to
18&nbsp;years and adults.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.5pt;text-indent:-28.5pt;line-height:
normal'><b><span lang=EN-GB>4.2<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></b><b><span lang=EN-GB>Posology and method of administration</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Treatment must
be initiated and monitored by an experienced gastroenterologist/hepatologist or
a paediatric gastroenterologist/hepatologist in the case of paediatric
patients.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Default><span style='font-size:11.0pt'>In case of persistent lack of
therapeutic response to cholic acid monotherapy, other treatment options should
be considered (see section 4.4). Patients should be monitored as follows: 3-monthly
during the first year, 6&#8209;monthly during the subsequent three years and
annually thereafter (see below).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Posology</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The dose must be
adjusted for each patient in a specialised unit according to blood and/or urine
chromatographic bile acid profiles.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>3&#946;&#8209;Hydroxy&#8209;&#916;<sup>5</sup>&#8209;C<sub>27</sub>&#8209;steroid
oxidoreductase deficiency</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The daily dose
ranges from 5 to 15&nbsp;mg/kg in infants, children, adolescents and adults. In
all age groups, the minimum dose is 50&nbsp;mg and the dose is adjusted in
50&nbsp;mg steps. In adults, the daily dose should not exceed 500&nbsp;mg.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&#916;<sup>4</sup>&#8209;3&#8209;Oxosteroid&#8209;5&#946;&#8209;reductase
deficiency </span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The daily dose
ranges from 5 to 15&nbsp;mg/kg in infants, children, adolescents and adults. In
all age groups, the minimum dose is 50&nbsp;mg and the dose is adjusted in
50&nbsp;mg steps. In adults, the daily dose should not exceed 500&nbsp;mg.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The daily dose
may be divided if it consists of more than one capsule &nbsp;in order to mimic
the continuous production of cholic acid in the body and to reduce the number
of capsules that need to be taken per administration. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>During the
initiation of therapy and dose adjustment, serum and/or urine bile acid levels
should be monitored intensively (at least every three months during the first
year of treatment, every six months during the second year) using </span><span
lang=EN-GB>suitable analytical techniques</span><span lang=EN-GB>. The
concentrations of the abnormal bile acid metabolites synthesised in 3&#946;&#8209;Hydroxy&#8209;&#916;<sup>5</sup>&#8209;C<sub>27</sub>&#8209;steroid
oxidoreductase deficiency (3&#946;,&nbsp;7&#945;&#8209;dihydroxy- and
3&#946;,&nbsp;7&#945;,&nbsp;12&#945;&#8209;trihydroxy&#8209;5&#8209;cholenoic
acids) or in &#916;<sup>4</sup>&#8209;3&#8209;Oxosteroid&#8209;5&#946;&#8209;reductase
deficiency (3&#8209;oxo&#8209;7&#945;&#8209;hydroxy- and 3&#8209;oxo&#8209;7&#945;,&nbsp;l2&#945;&#8209;dihydroxy&#8209;4&#8209;cholenoic
acids) should be determined. At each investigation, the need for dose
adjustment should be considered. The lowest dose of cholic acid that
effectively reduces the bile acid metabolites to as close to zero as possible
should be chosen. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Patients that
have previously been treated with other bile acids or other cholic acid
preparations should be closely monitored in the same manner during the
initiation of treatment with Orphacol. The dose should be adjusted accordingly,
as described above. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Liver parameters
should also be monitored, preferentially more frequently than serum and/or
urine bile acid levels. Concurrent elevation of serum gamma glutamyltransferase
(GGT), alanine aminotransferase (ALT) and/or serum bile acids above normal
levels may indicate overdose. Transient elevations of transaminases at the
initiation of cholic acid treatment have been observed and do not indicate the
need for a dose reduction if GGT is not elevated and if serum bile acid levels
are falling or in the normal range.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>After the
initiation period, serum and/or urine bile acids (using </span><u><span
lang=EN-GB>suitable analytical techniques</span></u><span lang=EN-GB>) and
liver parameters should be determined annually, at a minimum, and the dose
adjusted accordingly. Additional or more frequent investigations should be
undertaken to monitor therapy during periods of fast growth, concomitant
disease and pregnancy (see section&nbsp;4.6).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Special
populations</span></u></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>Elderly
population (&#8805;65&nbsp;years old) </span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>There is no
experience in elderly patients. The dose of cholic acid should be adjusted
individually.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>Renal
impairment </span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>No data are
available for patients with renal impairment. The dose of cholic acid should be
adjusted individually.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>Hepatic
impairment </span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Limited data are
available for patients with minor to severe hepatic impairment related to
3&#946;&#8209;Hydroxy&#8209;&#916;<sup>5</sup>&#8209;C<sub>27</sub>&#8209;steroid
oxidoreductase deficiency or &#916;<sup>4</sup>&#8209;3&#8209;Oxosteroid&#8209;5&#946;&#8209;reductase
deficiency. Patients are expected to present with some degree of hepatic
impairment at diagnosis, which improves under cholic acid therapy. The dose of
cholic acid should be adjusted individually.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>No experience
exists in patients with hepatic impairment from causes other than 3&#946;&#8209;Hydroxy&#8209;&#916;<sup>5</sup>&#8209;C<sub>27</sub>&#8209;steroid
oxidoreductase deficiency or &#916;<sup>4</sup>&#8209;3&#8209;Oxosteroid&#8209;5&#946;&#8209;reductase
deficiency and no dose recommendation can be given. Patients with hepatic
impairment should be monitored closely (see section 4.4).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>Familial
hypertriglyceridemia</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Patients with
newly diagnosed or a family history of familial hypertriglyceridemia are
expected to poorly absorb cholic acid in the intestine. The cholic acid dose
for patients with familial hypertriglyceridemia will have to be established and
adjusted as described, but an elevated dose, notably higher than the
500&nbsp;mg daily limit for adult patients, may be required and safe.</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>Paediatric
population</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Cholic acid
therapy has been used for infants from one month of age, and for children and
adolescents. The dose recommendations reflect the use in this population. The
daily dose in infants from 1&nbsp;month to 2&nbsp;years of age, children and
adolescents ranges from 5 to 15&nbsp;mg/kg and must be adjusted individually
for each patient.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Method of
administration</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Orphacol
capsules must be taken with food at approximately the same time each day, in
the morning and/or evening. Administration with food may increase cholic acid
bioavailability and improve tolerability. Regular and fixed times of
administration support the patient&#8217;s or caregiver&#8217;s compliance. Capsules
must be swallowed whole with water, without chewing.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>For infants and
children who cannot swallow capsules, the capsules may be opened and the
content added to infant formula or juice. For additional information, see
section 6.6.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>4.3&nbsp;&nbsp;&nbsp;&nbsp; Contraindications</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Hypersensitivity
to the active substance or to any of the excipients listed in section 6.1.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Concomitant use
of phenobarbital with cholic acid (see section&nbsp;4.5).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>4.4&nbsp;&nbsp;&nbsp;&nbsp; Special warnings and
precautions for use</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Cases of severe
hepatotoxicity, including cases with fatal outcome, have been reported, with
the use of cholic acid. Treatment with cholic acid in patients with pre-existing
hepatic impairment should be given under close monitoring and, for all patients
should be stopped if abnormal hepatocellular function, as measured by
prothrombin time, does not improve within 3&nbsp;months of the initiation of
cholic acid treatment. A concomitant decrease of urine total bile acids should
be observed. Treatment should be stopped earlier if there are clear indicators
of severe hepatic failure.</span></p>

<p class=MsoNormal style='line-height:normal'><u><span style='text-decoration:
 none'>&nbsp;</span></u></p>

<p class=MsoNormal style='line-height:normal'><u>Familial hypertriglyceridemia</u></p>

<p class=MsoNormal style='line-height:normal'>Patients with newly diagnosed or
a family history of familial hypertriglyceridaemia may have poor absorption of
cholic acid from the intestine. The dose of cholic acid in such patients should
be established and adjusted as described, but an elevated dose, notably higher
than the 500 mg daily limit for adult patients, may be required&#8221;. </p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=FR>Excipients</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=FR>Orphacol capsules
contain lactose. </span><span lang=EN-GB>Patients with rare hereditary problems
of galactose intolerance, total lactase deficiency or glucose-galactose
malabsorption should not take this medicinal product.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>4.5&nbsp;&nbsp;&nbsp;&nbsp; Interaction with other
medicinal products and other forms of interaction</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Phenobarbital
antagonises the effect of cholic acid. Use of phenobarbital in patients with
3&#946;&#8209;Hydroxy&#8209;&#916;<sup>5</sup>&#8209;C<sub>27</sub>&#8209;steroid
oxidoreductase deficiency or &#916;<sup>4</sup>&#8209;3&#8209;Oxosteroid&#8209;5&#946;&#8209;reductase
deficiency treated with cholic acid is contraindicated (see section 4.3).
Alternative treatments should be used.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Ciclosporin
alters the pharmacokinetics of cholic acid by inhibition of the hepatic uptake
and hepatobiliary secretion of bile acids, as well as its pharmacodynamics by
inhibition of cholesterol 7&#945;&#8209;hydroxylase. Co-administration should
be avoided. If administration of ciclosporin is considered necessary, serum and
urine bile acid levels should be closely monitored and the cholic acid dose adjusted
accordingly.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Bile acid
sequestrants (cholestyramine, colestipol, colesevelam) and certain antacids
(e.g. aluminium hydroxide) bind bile acids and lead to their elimination.
Administration of these medicinal products is expected to reduce the effect of
cholic acid. The dose of bile acid sequestrants or antacids must be separated
from the dose of cholic acid by an interval of 5&nbsp;hours, regardless of
which medicinal product is administered first.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The effect of
food on the bioavailability of cholic acid has not been studied.&nbsp; There is
a theoretical possibility that administration with food may increase cholic
acid bioavailability and improve tolerability.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>4.6&nbsp;&nbsp;&nbsp;&nbsp; </span></b><b><span
lang=EN-GB>Fertility, p</span></b><b><span lang=EN-GB>regnancy and lactation</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Women of
childbearing potential</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>There is no need
for contraceptive measures in women of childbearing potential treated with
cholic acid or their partners. Women of childbearing potential should conduct a
pregnancy test as soon as a pregnancy is suspected.</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Pregnancy</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>There is a
limited amount of data (less than 20 pregnancy outcomes) from the use of cholic
acid in pregnant women. The exposed pregnancies showed no adverse reactions to
cholic acid and resulted in normal, healthy children. Animal studies do not
indicate direct or indirect harmful effects with respect to reproductive
toxicity (see section&nbsp;5.3). </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>It is extremely
important that pregnant women continue their therapy during pregnancy.</span><span
lang=EN-GB> As a precautionary measure, pregnant women and their unborn
children should be closely monitored. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Breastfeeding</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Cholic acid and
its metabolites are excreted in human milk, but at therapeutic doses of
Orphacol, no effects on the breastfed newborns/infants are anticipated.
Orphacol can be used during breast-feeding.</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Fertility</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>No data on the
effects of cholic acid on fertility are available. At therapeutic doses, no
effect on fertility is anticipated.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>4.7&nbsp;&nbsp;&nbsp;&nbsp; Effects on ability to
drive and use machines</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Cholic acid has no
or neglible influence on the ability to drive and use machines.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.5pt;text-indent:-28.5pt;line-height:
normal'><b><span lang=EN-GB>4.8<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></b><b><span lang=EN-GB>Undesirable effects</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Summary of
the safety profile </span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Due to the
rarity of the diseases, the information about the most serious and/or most
frequently occurring adverse reactions is limited. Diarrhoea, increased
transaminases and pruritus have been associated with overdosage and disappeared
after dose reduction. Development of gallstones associated with long-term
treatment have been reported in very limited number of patients.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Tabulated
list of adverse reactions</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The following
table lists adverse reactions reported in the literature under treatment with
cholic acid. The frequency of these reactions is not known (cannot be estimated
from the available data).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="100%"
 style='width:100.0%;border-collapse:collapse;border:none'>
 <tr>
  <td width="50%" valign=top style='width:50.0%;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>MedDRA
  System Organ Class</span></b></p>
  </td>
  <td width="50%" valign=top style='width:50.0%;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Adverse
  reaction</span></b></p>
  </td>
 </tr>
 <tr>
  <td width="50%" valign=top style='width:50.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Gastrointestinal
  disorders</span></p>
  </td>
  <td width="50%" valign=top style='width:50.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Diarrhoea</span></p>
  </td>
 </tr>
 <tr>
  <td width="50%" valign=top style='width:50.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Hepatobiliary
  disorders</span></p>
  </td>
  <td width="50%" valign=top style='width:50.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Transaminases
  increased</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Gallstones</span></p>
  </td>
 </tr>
 <tr>
  <td width="50%" valign=top style='width:50.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Skin and
  subcutaneous tissue disorders</span></p>
  </td>
  <td width="50%" valign=top style='width:50.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Pruritus </span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><u><span lang=EN-GB>Description
of selected adverse reactions</span></u><span lang=EN-GB> </span><span
lang=EN-GB>The development of pruritus and/or diarrhoea has been observed
during treatment with Orphacol. These reactions abated after dose reduction and
are suggestive of overdose. Patients presenting with pruritus and/or persistent
diarrhoea should be investigated for a potential overdose by a serum and</span><span
lang=EN-GB>/or urine</span><span lang=EN-GB> bile acid assay (see section 4.9).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Gallstones have
been reported after long-term therapy.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Paediatric
population </span></u><span lang=EN-GB>The presented safety information is
derived principally from paediatric patients. The available literature is not
sufficient to detect a difference in the safety of cholic acid within
paediatric age groups or between paediatric patients and adults.</span></p>

<p class=MsoNormal style='text-align:justify;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Other special
populations</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Please refer to
section 4.2 for use of Orphacol in special populations.</span></p>

<p class=MsoNormal style='text-align:justify;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><u><span lang=EN-GB>Reporting of
suspected adverse reactions</span></u></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Reporting
suspected adverse reactions after authorisation of the medicinal product is
important. It allows continued monitoring of the benefit/risk balance of the
medicinal product. Healthcare professionals are asked to report any suspected
adverse reactions via <span style='background:silver'>the national reporting
system listed in <a
href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc">Appendix
V</a></span>.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>4.9&nbsp;&nbsp;&nbsp;&nbsp; Overdose</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Episodes of
symptomatic overdose have been reported, including accidental overdose.
Clinical features were limited to pruritus and diarrhoea. Laboratory tests
showed elevation of serum gamma glutamyltransferase (GGT) transaminases and
serum bile acid concentrations. Reduction of the dose led to resolution of the
clinical signs and correction of abnormal laboratory parameters.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In the case of
an accidental overdose, treatment should be continued at the recommended dose
after normalisation of clinical signs and/or biological abnormalities.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACOLOGICAL
PROPERTIES</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>5.1&nbsp;&nbsp;&nbsp;&nbsp; Pharmacodynamic
properties</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Pharmacotherapeutic
group: Bile and liver therapy, bile acid and derivatives, ATC code: A05AA03 </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Cholic acid is
the predominant primary bile acid in man. In patients with </span><span
lang=EN-GB>inborn deficiency of 3&#946;&#8209;Hydroxy&#8209;&#916;<sup>5</sup>&#8209;C<sub>27</sub>&#8209;steroid
oxidoreductase and &#916;<sup>4</sup>&#8209;3&#8209;Oxosteroid&#8209;5&#946;&#8209;reductase,
the biosynthesis of primary bile acids is reduced or absent. Both inborn
diseases are extremely rare, with a prevalence in Europe of about 3 to 5
patients with 3&#946;&#8209;Hydroxy&#8209;&#916;<sup>5</sup>&#8209;C<sub>27</sub>&#8209;steroid
oxidoreductase deficiency per 10 million inhabitants, and an estimated ten-fold
lower prevalence for &#916;<sup>4</sup>&#8209;3&#8209;Oxosteroid&#8209;5&#946;&#8209;reductase
deficiency. In the absence of treatment, unphysiologic cholestatic and
hepatotoxic bile acid metabolites are predominant in the liver, serum and
urine. The rational basis for treatment consists of restoration of the bile
acid-dependent component of bile flow enabling restoration of biliary secretion
and biliary elimination of toxic metabolites; inhibition of the production of
the toxic bile acid metabolites by negative feedback on cholesterol 7&#945;&#8209;hydroxylase,
which is the rate-limiting enzyme in bile acid synthesis; and improvement of the
patient&#8217;s nutritional status by correcting intestinal malabsorption of
fats and fat-soluble vitamins.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Clinical
experience has been reported in the literature from small cohorts of patients
and single case reports; absolute patient numbers are small due to the rarity
of the conditions. This rarity also made the conduct of controlled clinical
studies impossible. Overall, cholic acid treatment results for about 60
patients with 3&#946;&#8209;Hydroxy&#8209;&#916;<sup>5</sup>&#8209;C<sub>27</sub>&#8209;steroid
oxidoreductase deficiency are reported in the literature. Detailed long-term
data on treatment with cholic acid monotherapy are available for 14 patients
observed for up to 12.9 years. Cholic acid treatment results for seven patients
with &#916;<sup>4</sup>&#8209;3&#8209;Oxosteroid&#8209;5&#946;&#8209;reductase
deficiency for up to 14 years are reported in the literature. Detailed medium-
to long-term data are available for 5 of these patients, of whom 1 has been
treated with cholic acid monotherapy. Oral cholic acid therapy has been shown
to: postpone or obviate the need for liver transplantation; restore normal
laboratory parameters; improve histological lesions of the liver, and significantly
improve all of the patient&#8217;s symptoms. Mass spectrometry analysis of
urine during cholic acid therapy shows the presence of cholic acid and a marked
reduction, or even complete elimination of the toxic bile acid metabolites.
This reflects restoration of an effective feedback control of bile acid
synthesis and a metabolic equilibrium. In addition, blood cholic acid
concentration was normal and fat-soluble vitamins were restored to their normal
range.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Paediatric
population</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The clinical
experience reported in the literature is from a patient population with inborn
deficiency of 3&#946;&#8209;Hydroxy&#8209;&#916;<sup>5</sup>&#8209;C<sub>27</sub>&#8209;steroid
oxidoreductase or &#916;<sup>4</sup>&#8209;3&#8209;Oxosteroid&#8209;5&#946;&#8209;reductase
that includes principally infants from the age of one month, children and
adolescents. However, absolute numbers of cases are small.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>This medicinal
product has been authorised under &#8220;Exceptional Circumstances&#8221;.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>This means that
due to the rarity of the disease and for ethical reasons it has not been
possible to obtain complete information on this medicinal product.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The European
Medicines Agency will review any new information which may become available
every year and this SmPC will be updated as necessary.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>5.2&nbsp;&nbsp;&nbsp;&nbsp; Pharmacokinetic
properties</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Cholic acid, a primary bile acid, is partially absorbed in the
ileum. The remaining part is transformed by reduction of the 7&#945;&#8209;hydroxy
group to deoxycholic acid (3&#945;,&nbsp;12&#945;&#8209;dihydroxy) by
intestinal bacteria. Deoxycholic acid is a secondary bile acid. More than 90%
of the primary and secondary bile acids are reabsorbed in the ileum by a
specific active transporter and are recycled to the liver by the portal vein;
the remainder is excreted in the faeces. A small fraction of bile acids is
excreted in urine.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>5.3&nbsp;&nbsp;&nbsp;&nbsp; Preclinical safety data</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The available
non-clinical data in the literature reveal no special hazard for humans based
on studies of safety pharmacology, repeated dose toxicity, genotoxicity,
carcinogenic potential and toxicity to reproduction. The studies have however
not been conducted to the same level of detail as for a pharmaceutical agent,
as cholic acid is a physiological substance in animals and humans.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The intravenous
LD<sub>50</sub> of cholic acid in mice is 350&nbsp;mg/kg body weight.
Parenteral administration may cause haemolysis and cardiac arrest. Administered
orally, bile acids and salts generally have only a minor toxic potential. The
oral LD<sub>50</sub> in mice is 1520&nbsp;mg/kg. In repeated-dose studies,
frequently reported effects of cholic acid have included decreased body weight,
diarrhoea and liver damage with elevated transaminases. Increased liver weight
and gallstones have been reported in repeated dose studies in which cholic acid
was co-administered with cholesterol. </span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Cholic acid
showed non-significant mutagenic activity in a battery of genotoxicity tests
performed <i>in vitro</i>. Animal studies showed that cholic acid did not
induce any teratogenic effect or foetal toxicity.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACEUTICAL
PARTICULARS</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>6.1&nbsp;&nbsp;&nbsp;&nbsp; List of excipients</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Capsule content:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lactose
monohydrate, </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Colloidal
anhydrous silica,</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Magnesium
stearate.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Capsule shell:</span></p>

<p class=MsoNormal style='line-height:normal'>Gelatin (bovine origin),</p>

<p class=MsoNormal style='line-height:normal'><span lang=IT>Titanium dioxide
(E171),</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=IT>Carmine blue
(E132),</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Yellow Iron
Oxide (E172).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>6.2&nbsp;&nbsp;&nbsp;&nbsp; Incompatibilities</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Not applicable.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>6.3&nbsp;&nbsp;&nbsp;&nbsp; Shelf life</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>3&nbsp;years</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>6.4&nbsp;&nbsp;&nbsp;&nbsp; Special precautions for
storage</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Store below
30&deg;C.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.5pt;text-indent:-28.5pt;line-height:
normal'><b><span lang=EN-GB>6.5<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></b><b><span lang=EN-GB>Nature and contents of container</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>PVC</span><span
lang=BG>/</span>PVDC<span lang=EN-GB>-aluminium blister of 10&nbsp;capsules.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Pack sizes: 30,
60, 120. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Not all pack
sizes may be marketed.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>6.6&nbsp;&nbsp;&nbsp;&nbsp; Special precautions for
disposal and other handling</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>Use in the
paediatric population</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>See also
section&nbsp;4.2. For infants and children who cannot swallow capsules, the
capsules may be opened and the content added to infant formula or
infant-adapted apple/orange or apple/apricot juice. Other food such as fruit
compote or yoghurt may be suitable for administration, but no data on the
compatibility or palatability are available.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Any unused
product or waste material should be disposed of in accordance with local
requirements.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=FR>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; MARKETING
AUTHORISATION HOLDER</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=FR>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=FR>Laboratoires CTRS</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=FR>63, rue de
l&#8217;Est</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=FR>92100
Boulogne-Billancourt</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=FR>France</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=FR>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=FR>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=FR>8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; MARKETING
AUTHORISATION NUMBER(S) </span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=FR>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=FR>EU/1/13/870/004</span><span
lang=FR> </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=FR>EU/1/13/870/005</span><span
lang=FR> </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EU/1/13/870/006</span><span
lang=EN-GB> </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; DATE OF
FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Date of first
authorisation: 12 September 2013</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Date of latest
renewal: 24 April 2019</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>10.&nbsp;&nbsp;&nbsp;&nbsp; DATE OF REVISION OF THE
TEXT</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Detailed information on this medicinal product </span><span
lang=EN-GB>is available on the website of the European Medicines Agency <span
style='color:blue'><a href="http://www.ema.europa.eu/">http://www.ema.europa.eu</a></span></span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>ANNEX II</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:70.8pt;margin-bottom:
0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:70.8pt;margin-bottom:
0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-35.4pt;line-height:
normal'><b><span lang=EN-GB>A.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; MANUFACTURER(S)
RESPONSIBLE FOR BATCH RELEASE</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:70.8pt;margin-bottom:
0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-35.4pt;line-height:
normal'><b><span lang=EN-GB>B.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; CONDITIONS
OR RESTRICTIONS REGARDING SUPPLY AND USE </span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:70.8pt;margin-bottom:
0in;margin-left:56.7pt;margin-bottom:.0001pt;text-indent:-7.05pt;line-height:
normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:70.8pt;margin-bottom:
0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-35.4pt;line-height:
normal'><b><span lang=EN-GB>C.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OTHER CONDITIONS
OR RESTRICTIONS OF THE MARKETING AUTHORISATION</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:70.8pt;margin-bottom:
0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-35.4pt'><b><span
lang=EN-GB>D.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
lang=EN-GB style='text-transform:uppercase'>conditions or restrictions with
regard to the safe and effective use of the medicinal product</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:70.8pt;margin-bottom:
0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-35.4pt;line-height:
normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:70.8pt;margin-bottom:
0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-35.4pt;line-height:
normal'><b><span lang=EN-GB>E.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIFIC
OBLIGATIONS TO </span><span lang=EN-GB>COMPLETE POST-AUTHORISATION MEASURES FOR
THE MARKETING AUTHORISATION UNDER EXCEPTIONAL CIRCUMSTANCES</span></b></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>A.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; MANUFACTURER(S)
RESPONSIBLE FOR BATCH RELEASE</span></b></p>

<p class=MsoNormal style='margin-right:70.8pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Name and
address of the manufacturer(s) responsible for batch release</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=FR>Laboratoires CTRS</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=FR>63, rue de l'Est</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=FR>92100 Boulogne-Billancourt</span></p>

<p class=MsoNormal style='line-height:normal'>France</p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>B.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; CONDITIONS OR
RESTRICTIONS REGARDING SUPPLY AND USE</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Medicinal
product subject to restricted medical prescription (See Annex I: Summary of
Product Characteristics, section 4.2).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>C. &nbsp;&nbsp;&nbsp;&nbsp; OTHER
CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION</span></b></p>

<p class=MsoNormal style='margin-right:-.05pt'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.05pt;margin-bottom:
0in;margin-left:.5in;margin-bottom:.0001pt;text-indent:-.5in'><span lang=EN-GB
style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>Periodic Safety Update Reports</span></b></p>

<p class=MsoNormal style='margin-right:28.35pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:28.35pt'><span lang=EN-GB>The
requirements for submission of periodic safety update reports for this
medicinal product are set out in the list of Union reference dates (EURD list)
provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent
updates published on the European medicines web-portal. </span></p>

<p class=MsoNormal style='margin-right:28.35pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>D.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; CONDITIONS OR RESTRICTIONS WITH
REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT&nbsp; </span></b></p>

<p class=MsoNormal style='margin-right:-.05pt'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.05pt;margin-bottom:
0in;margin-left:.5in;margin-bottom:.0001pt;text-indent:-.5in'><span lang=EN-GB
style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>Risk Management Plan (RMP)</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.05pt;margin-bottom:
0in;margin-left:.5in;margin-bottom:.0001pt'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal'><span
lang=EN-GB>The MAH shall perform the required pharmacovigilance activities and
interventions detailed in the agreed RMP presented in Module 1.8.2 of the
Marketing Authorisation and any agreed subsequent updates of the RMP.</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal'><span
lang=EN-GB>An updated RMP should be submitted:</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.05pt;margin-bottom:
0in;margin-left:.5in;margin-bottom:.0001pt;text-indent:-.25in'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>At the request of the European Medicines Agency;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.05pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-10.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Whenever the risk management system is modified,
especially as the result of new information being received that may lead to a
significant change to the benefit/risk profile or as the result of an important
(pharmacovigilance or risk minimisation) milestone being reached.</span></p>

<p class=MsoNormal style='margin-right:-.05pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.05pt;margin-bottom:
0in;margin-left:.5in;margin-bottom:.0001pt;text-indent:-.5in'><span lang=EN-GB
style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>Additional risk minimisation measures</span></b></p>

<p class=MsoNormal style='margin-right:-.05pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The MAH, in
agreement with the competent authorities in the Member States, shall implement,
prior to the launch, an educational programme for physicians aiming </span><span
lang=EN-GB>to</span><span lang=EN-GB> provide educational material on correct
diagnosis and therapeutic management</span><span lang=EN-GB>s</span><span
lang=EN-GB> of the treatment of inborn errors in primary bile acid synthesis
due to 3&#946;-Hydroxy-&#916;<sup>5</sup>-C<sub>27</sub>-steroid oxidoreductase
deficiency or &#916;<sup>4</sup>-3-Oxosteroid-5&#946;-reductase deficiency </span><span
lang=EN-GB>and </span><span lang=EN-GB>to inform on expected and potential
risks associated with the treatment. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:28.35pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>The physician educational programme should contain the
following key elements:</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:28.35pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:28.35pt;margin-bottom:
0in;margin-left:.25in;margin-bottom:.0001pt;text-indent:-.25in;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Prescription of a supratherapeutic dose (MedDRA
term: drug toxicity)</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:28.35pt;margin-bottom:
0in;margin-left:.25in;margin-bottom:.0001pt;text-indent:-.25in;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Risk of gallstones</span></p>

<p class=MsoNormal style='margin-right:28.35pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:28.35pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.05pt'><b><span lang=EN-GB>E.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIFIC
OBLIGATION TO COMPLETE POST-AUTHORISATION MEASURES FOR THE MARKETING
AUTHORISATION UNDER EXCEPTIONAL CIRCUMSTANCES</span></b></p>

<p class=MsoNormal style='margin-right:-.05pt'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-right:-.05pt'><span lang=EN-GB>This being an
approval under exceptional circumstances and pursuant to Article 14(8) of
Regulation (EC) No 726/2004, the MAH shall conduct, within the stated timeframe,
the following measures:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=662
 style='width:6.9in;border-collapse:collapse;border:none'>
 <tr>
  <td width=546 valign=top style='width:409.4pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  lang=EN-GB>Description</span></b></p>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width=117 valign=top style='width:87.4pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  lang=EN-GB>Due Date</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=546 valign=top style='width:409.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>CTRS </span>commits to monitor <span
  lang=EN-GB>the safety and efficacy </span><span lang=EN-GB>in patients
  treated with Orphacol</span><span lang=EN-GB> from a patient surveillance
  database for which the protocol has been endorsed by the CHMP and is
  documented in the</span><span lang=EN-GB> Orphacol</span><span lang=EN-GB>
  RMP. </span></p>
  <p class=MsoNormal><span lang=EN-GB>The objectives of this surveillance
  programme is to monitor accumulating data on efficacy and safety in the
  treatment of inborn errors in primary bile acid synthesis due to 3&#946;&#8209;Hydroxy&#8209;&#916;<sup>5</sup>&#8209;C<sub>27</sub>&#8209;steroid
  oxidoreductase deficiency or &#916;<sup>4</sup>&#8209;3&#8209;Oxosteroid&#8209;5&#946;&#8209;reductase
  deficiency with Orphacol in infants, children, adolescents and adults.</span></p>
  <p class=MsoNormal>Reports on recruitment progress of the <span lang=EN-GB>patient
  surveillance database</span><span lang=EN-GB> </span><span lang=EN-GB>will be
  analysed and reported to the CHMP at the time of PSURs (for safety) and of
  the Annual Re-assessments (for efficacy and safety)</span>. Progress and
  results from the database will form the basis of the annual reassessments of
  the benefit/risk profile of Orphacol<span lang=EN-GB>.</span></p>
  </td>
  <td width=117 valign=top style='width:87.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>- PSUR</span></p>
  <p class=MsoNormal><span lang=EN-GB>- Annual Re-assessment</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:28.3pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>ANNEX III</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>LABELLING AND PACKAGE LEAFLET</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB
style='color:green'>&nbsp;</span></i></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>A. LABELLING</span></b></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black'><br clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>PARTICULARS TO APPEAR ON THE OUTER PACKAGING</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>CARTON</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME
OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Orphacol
50&nbsp;mg hard capsules</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Cholic acid</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; STATEMENT
OF ACTIVE SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Each hard
capsule contains 50&nbsp;mg cholic acid.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; LIST
OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Contains
lactose. See the package leaflet for further information.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACEUTICAL
FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>30 hard capsules</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:silver'>60 hard capsules</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:silver'>120 hard capsules</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; METHOD
AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Do not chew.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Read the package
leaflet before use.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Oral use.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF
CHILDREN</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Keep out of the
reach and sight of children.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OTHER
SPECIAL WARNING(S), IF NECESSARY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
STORAGE CONDITIONS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>Store below 30&deg;C.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>10.&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL PRECAUTIONS FOR DISPOSAL OF
UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL
PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>11.&nbsp;&nbsp;&nbsp;&nbsp; NAME AND ADDRESS OF THE MARKETING
AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=FR>Laboratoires CTRS</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=FR>63, rue de
l&#8217;Est</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=FR>92100
Boulogne-Billancourt</span></p>

<p class=MsoNormal style='line-height:normal'>France</p>

<p class=MsoNormal style='line-height:normal'>E-mail: ctrs@ctrs.fr</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>12.&nbsp;&nbsp;&nbsp;&nbsp; MARKETING AUTHORISATION NUMBER(S)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=NO-NYN>EU/1/13/870/00</span><span
lang=ET>1</span><span lang=ET> </span><span lang=NO-NYN style='background:silver'>[30
hard capsules]</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=NO-NYN
style='background:silver'>EU/1/13/870/002</span><span lang=NO-NYN
style='background:silver'> [60 hard capsules]</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:silver'>EU/1/13/870/00</span><span lang=ET style='background:
silver'>3</span><span lang=EN-GB style='background:silver'> [120 hard capsules]</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>13.&nbsp;&nbsp;&nbsp;&nbsp; BATCH NUMBER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lot</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>14.&nbsp;&nbsp;&nbsp;&nbsp; GENERAL CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:2.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>15.&nbsp;&nbsp;&nbsp;&nbsp; INSTRUCTIONS ON USE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>16.&nbsp;&nbsp;&nbsp;&nbsp; INFORMATION IN BRAILLE</span></b></p>

</div>

<p class=MsoBodyText><span lang=EN-GB style='color:windowtext'>&nbsp;</span></p>

<p class=MsoBodyText><span lang=EN-GB style='color:windowtext;display:none'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black;background:#CCCCCC'>Justification for not including Braille
accepted</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:#CCCCCC'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:#CCCCCC'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='display:none'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='display:none'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='display:none'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>17.&nbsp;&nbsp;&nbsp;&nbsp; UNIQUE IDENTIFIER &#8211; 2D BARCODE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:silver'>2D barcode carrying the unique identifier included.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:#CCCCCC'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>18.&nbsp;&nbsp;&nbsp;&nbsp; UNIQUE IDENTIFIER - HUMAN READABLE DATA</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>PC: {number} </span></p>

<p class=MsoNormal><span lang=EN-GB>SN: {number} </span></p>

<p class=MsoNormal><span lang=EN-GB>NN: {number} </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='display:none'>&nbsp;</span></p>

<b><u><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black'><br clear=all style='page-break-before:always'>
</span></u></b>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>PARTICULARS TO APPEAR ON THE OUTER PACKAGING</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>CARTON</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME
OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Orphacol 250&nbsp;mg
hard capsules</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Cholic acid</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; STATEMENT
OF ACTIVE SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Each hard
capsule contains 250&nbsp;mg cholic acid.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; LIST
OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Contains
lactose. See the package leaflet for further information.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACEUTICAL
FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>30 hard capsules</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:silver'>60 hard capsules</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:silver'>120 hard capsules</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; METHOD
AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Do not chew.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Read the package
leaflet before use.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Oral use.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF
CHILDREN</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Keep out of the
reach and sight of children.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OTHER
SPECIAL WARNING(S), IF NECESSARY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
STORAGE CONDITIONS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>Store below 30&deg;C.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>10.&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL PRECAUTIONS FOR DISPOSAL OF
UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS,
IF APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>11.&nbsp;&nbsp;&nbsp;&nbsp; NAME AND ADDRESS OF THE MARKETING
AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=FR>Laboratoires CTRS</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=FR>63, rue de
l&#8217;Est</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=FR>92100
Boulogne-Billancourt</span></p>

<p class=MsoNormal style='line-height:normal'>France</p>

<p class=MsoNormal style='line-height:normal'>E-mail: ctrs@ctrs.fr</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>12.&nbsp;&nbsp;&nbsp;&nbsp; MARKETING AUTHORISATION NUMBER(S) </span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=NO-NYN>EU/1/13/870/004</span><span
lang=NO-NYN> <span style='background:silver'>[30 hard capsules]</span></span></p>

<p class=MsoNormal style='line-height:normal'><span lang=NO-NYN
style='background:silver'>EU/1/13/870/005</span><span lang=NO-NYN
style='background:silver'> [60 hard capsules]</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:silver'>EU/1/13/870/006</span><span lang=EN-GB
style='background:silver'> [120 hard capsules]</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>13.&nbsp;&nbsp;&nbsp;&nbsp; BATCH NUMBER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lot</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>14.&nbsp;&nbsp;&nbsp;&nbsp; GENERAL CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:2.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>15.&nbsp;&nbsp;&nbsp;&nbsp; INSTRUCTIONS ON USE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>16.&nbsp;&nbsp;&nbsp;&nbsp; INFORMATION IN BRAILLE</span></b></p>

</div>

<p class=MsoBodyText><span lang=EN-GB style='color:windowtext'>&nbsp;</span></p>

<p class=MsoBodyText><span lang=EN-GB style='color:windowtext;display:none'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black;background:#CCCCCC'>Justification for not including Braille
accepted</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:#CCCCCC'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:#CCCCCC'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='display:none'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='display:none'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>17.&nbsp;&nbsp;&nbsp;&nbsp; UNIQUE IDENTIFIER &#8211; 2D BARCODE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:silver'>2D barcode carrying the unique identifier included.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:#CCCCCC'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>18.&nbsp;&nbsp;&nbsp;&nbsp; UNIQUE IDENTIFIER - HUMAN READABLE DATA</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>PC: {number} </span></p>

<p class=MsoNormal><span lang=EN-GB>SN: {number} </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>NN: {number} </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='display:none'>&nbsp;</span></p>

<b><u><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></u></b>

<div style='border:solid windowtext 1.0pt;border-bottom:none;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS</span></b></p>

</div>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>BLISTERS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Orphacol
50&nbsp;mg capsules</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Cholic acid</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME OF THE MARKETING
AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Laboratoires
CTRS</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 2.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; EXPIRY DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; BATCH NUMBER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lot</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OTHER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black'><br clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='line-height:normal;background:white'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<div style='border:solid windowtext 1.0pt;border-bottom:none;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS</span></b></p>

</div>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>BLISTERS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Orphacol 250&nbsp;mg
capsules</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Cholic acid</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME OF THE MARKETING
AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Laboratoires
CTRS</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 2.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; EXPIRY DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; BATCH NUMBER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lot</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OTHER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:green'><br clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>B. PACKAGE LEAFLET</span></b></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>PACKAGE LEAFLET: INFORMATION FOR THE USER</span></b></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>Orphacol 50&nbsp;mg hard capsules</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>Orphacol 250&nbsp;mg hard capsules</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>Cholic acid</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB><img border=0 width=21 height=18
src="Orphacol%20S-33%20-%20PI%20-%20clea_files/image003.gif"></span><span
lang=EN-GB>This medicine is subject to additional monitoring. This will allow
quick identification of new safety information. You can help by reporting any
side effects you may get. See the end of section 4 for how to report side
effects.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>Read all of this leaflet carefully before you start
taking this medicine because it contains </span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>important information for you.</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Keep this leaflet. You may need to read it
again.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>If you have any further questions, ask your doctor
or pharmacist.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>This medicine has been prescribed for you. Do
not pass it on to others. It may harm them, even if their signs of illness are
the same as yours.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>If you get any side effects, talk to your doctor
or pharmacist. This includes any possible side effects not listed in this
leaflet. </span><span lang=EN-GB>See section 4.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><i><span
lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><b><span lang=EN-GB>What is in this leaflet</span></b><span lang=EN-GB>:</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; What Orphacol is
and what it is used for</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
lang=EN-GB>What you need to know b</span><span lang=EN-GB>efore you take Orphacol</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; How to take Orphacol</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Possible side
effects</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>How to store Orphacol</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
lang=EN-GB>Contents of the pack and other </span><span lang=EN-GB>information</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.5pt;margin-bottom:.0001pt;text-indent:-28.5pt;line-height:normal'><b><span
lang=EN-GB>1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></b><b><span lang=EN-GB>What Orphacol is and what it is used for</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Orphacol contains cholic acid, a bile acid which is normally
produced by the liver. Certain medical conditions are caused by defects in bile
acid production and Orphacol is used to treat infants from one month to
2&nbsp;years of age, children, adolescents and adults with these medical
conditions. The cholic acid contained in Orphacol replaces the bile acids that
are missing due to the defect in bile acid production.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.5pt;margin-bottom:.0001pt;text-indent:-28.5pt;line-height:normal'><b><span
lang=EN-GB>2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></b><b><span lang=EN-GB>What you need to know before you take
Orphacol</span></b></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Do not take
Orphacol</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are
allergic to cholic acid or any of the other ingredients of this medicine
(listed in section 6).</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are taking
phenobarbital, a medicine to treat epilepsy.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>Warnings and precautions</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>During your treatment, your doctor will carry out various blood and
urine tests at different time to see how your body is handling this medicine
and to help work out the dose that you need. More frequent tests will be needed
if you are growing fast, if you are ill (if you have e.g. liver problems), or
if you are pregnant.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>Other medicines and Orphacol</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Tell your doctor or pharmacist if you are taking, have recently
taken any </span><span lang=EN-GB>or might take </span><span lang=EN-GB>other
medicines.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Some medicines used to lower cholesterol levels, so-called bile acid
sequestrants (cholestyramine, colestipol, colesevelam), and medicines to treat
heartburn that contain aluminium may lessen the effect of Orphacol. If you take
these medicines, take Orphacol </span><span lang=EN-GB>at least 5&nbsp;hours
before or at least 5&nbsp;hours after taking these other medicines. </span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Ciclosporin (a medicine used to suppress the immune system) may also
change the effect of Orphacol. Please tell your doctor if you are taking ciclosporin.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>Pregnancy and breast-feeding</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Please consult
your doctor if you plan to become pregnant. Take a pregnancy test as soon as
you suspect you may be pregnant. It is very important to continue taking
Orphacol during pregnancy.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>If you become
pregnant during treatment with Orphacol, your doctor will decide which treatment
and dose is best in your situation. As a precaution, you and your unborn child
should be closely monitored during pregnancy.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Orphacol can be
used during breast-feeding. Tell your doctor if you plan to breast-feed or are
breast-feeding before you take Orphacol.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Ask your doctor
or pharmacist for advice before taking any medicine.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>Driving and using machines</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Orphacol is not expected to have an effect on the ability to drive
and use machines.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=FR>Orphacol contains lactose</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span lang=FR>Orphacol
contains a certain sugar (lactose monohydrate). </span><span lang=EN-GB>If you
have been told by your doctor that you have an intolerance to some sugars,
contact your doctor before taking Orphacol.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.5pt;margin-bottom:.0001pt;text-indent:-28.5pt;line-height:normal'><b><span
lang=EN-GB>3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></b><b><span lang=EN-GB>How to take Orphacol</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><i><span
lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Always take Orphacol exactly as your doctor has told you. Check with
your doctor if you are not sure.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>The usual starting dose is 5 to 15&nbsp;mg per kilogram body weight
every day in infants, children, adolescents and adults.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Before treatment your doctor will make an assessment from your
laboratory tests to determine the correct dose for you. The dose will then be
further adjusted by your doctor depending on your body&#8217;s response. </span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Orphacol capsules are taken by mouth with a meal at approximately
the same time each day, in the morning and/or evening. Taking Orphacol at
regular times with a meal will help you remember to take this medicine, and may
help your body to better take it up. Capsules must be swallowed whole with
water. Do not chew.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>If your doctor has prescribed a dose which requires you to take more
than one capsule per day, you and your doctor can decide how this will be taken
during the day. You may for example take one capsule in the morning and one in
the evening. This way, you will have to take fewer capsules at once. </span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>Use in children</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>For babies and children who cannot swallow capsules, </span><span
lang=EN-GB>the capsule can be opened and its contents added to baby formula or
apple/orange or apple/apricot juice adapted for small children.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>If you take more Orphacol than you should</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>If you have taken more Orphacol than you should, contact your doctor
as soon as possible. He will assess your laboratory test results and advise you
when you should resume your treatment with your normal dose.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><i><span
lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>If you forget to take Orphacol</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Take your next dose when you would normally take it. Do not take a
double dose to make up for a forgotten dose.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>If you stop taking Orphacol</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>There is a risk
of permanently damaging your liver if you stop taking Orphacol. You should
never stop taking Orphacol unless your doctor advises you to do so.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>If you have any
further questions on the use of this medicine, ask your doctor.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Possible
side effects</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>Like all medicines, this medicine can cause side effects, although
not everybody gets them.</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Several patients have experienced itching and/or diarrhoea, however,
it is not known how likely this is to occur (frequency cannot be estimated from
the available data). If itching and/or diarrhoea last for more than three days,
tell your doctor.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>For several patients an increase of liver enzymes (serum
transaminases) have been reported during the treatment with Orphacol (frequency
cannot be estimated from the available data). Your doctor will decide what to
do if this happens to you.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Gallstones have been reported after long-term therapy with Orphacol.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>Reporting of side effects</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>If you get any side effects, talk to your doctor.</span><span
lang=EN-GB style='color:red'> </span><span lang=EN-GB>This includes any
possible side effects not listed in this leaflet. You can also report side
effects directly via <span style='background:silver'>the national reporting
system listed in <a
href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc">Appendix
V</a></span></span><span lang=EN-GB>. By reporting side effects you can help
provide more information on the safety of this medicine.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; How to store
Orphacol</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Keep out of the reach and sight of children.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Do not use Orphacol after the expiry date which is stated on the
carton and blister after EXP. The expiry date refers to the last day of that
month.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Store below 30&deg;C.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Medicines should not be disposed of via wasterwater or household
waste. Ask your pharmacist how to dispose of medicines no longer required.
These measures will help to protect the environment.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Contents of the pack and
other information</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>What Orphacol contains </span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The active substance is cholic acid. <br>
<i>Orphacol 50&nbsp;mg</i>: Each hard capsule contains 50&nbsp;mg of cholic
acid.<i><br>
</i><i>Orphacol 250&nbsp;mg</i>: Each hard capsule contains 250&nbsp;mg of
cholic acid.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The other ingredients are:</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;line-height:normal'><u><span
lang=EN-GB>Content of capsules</span></u><span lang=EN-GB>: Lactose monohydrate
(see section 2 under &#8216;Orphacol contains lactose&#8217; for more
information), colloidal anhydrous silica, magnesium stearate</span></p>

<p class=MsoNormal style='margin-left:28.35pt;line-height:normal'><u><span
lang=EN-GB>Capsule shell</span></u><span lang=EN-GB>: </span></p>

<p class=MsoNormal style='margin-left:28.35pt;line-height:normal'><span
lang=EN-GB>Orphacol 50&nbsp;mg: gelatin, titanium dioxide (E171), carmine blue
(E132);</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;line-height:normal'><span lang=IT>Orphacol
250&nbsp;mg: gelatin, titanium dioxide (E171), carmine blue (E132), yellow iron
oxide (E172).</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span lang=IT>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>What Orphacol looks like and contents of the pack</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Orphacol is available
as hard capsules (capsules) of oblong shape. Capsules of 50&nbsp;mg cholic acid
are blue and white and capsules of 250&nbsp;mg cholic acid are green and white.
They are contained in blisters of 10&nbsp;capsules each.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Pack sizes are
available in 30, 60 and 120&nbsp;capsules.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Not all pack
sizes may be marketed.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>Marketing Authorisation Holder and Manufacturer</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><u>Marketing
Authorisation Holder</u></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span lang=FR>Laboratoires
CTRS</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span lang=FR>63,
rue de l&#8217;Est</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span lang=FR>92100
Boulogne-Billancourt</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span lang=FR>France</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span lang=FR>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><u><span
lang=FR>Manufacturer</span></u></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=FR>Laboratoires CTRS</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=FR>63, rue de l'Est</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>92100
Boulogne-Billancourt</p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'>France</p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>For any information about this medicine, please contact the local
representative of the Marketing Authorisation Holder:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=624
 style='margin-left:-1.7pt;border-collapse:collapse'>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.3pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=FR>Belgi&euml;/Belgique/Belgien</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=FR>Laboratoires CTRS</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=FR>T&eacute;l/Tel:
  +32 (0)2 40 11 442</span></p>
  <p class=MsoNormal style='margin-right:1.7pt;line-height:normal'><span
  lang=FR><a href="mailto:ctrs@ctrs.fr"><span style='color:windowtext;
  text-decoration:none'>ctrs@ctrs.fr &nbsp;</span></a></span></p>
  <p class=MsoNormal style='margin-right:1.7pt;line-height:normal'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:3.25in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
  lang=IT>Lietuva</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=IT>Immedica Pharma
  AB</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=IT>Tel/Puh: +46 (0)8
  533 39 500 </span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=DE><a
  href="mailto:info@immedica.com"><span style='color:windowtext;text-decoration:
  none'>info@immedica.com</span></a></span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.3pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
  lang=EN-GB>&#1041;&#1098;&#1083;&#1075;&#1072;&#1088;&#1080;&#1103;</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=FR>Laboratoires CTRS</span></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=FR>Te</span><span lang=EN-GB>&#1083;</span><span lang=FR>.: + 33
  (0)1&nbsp;707 60 637</span></p>
  <p class=MsoNormal style='margin-right:1.7pt;line-height:normal'><span
  lang=FR><a href="mailto:ctrs@ctrs.fr"><span style='color:windowtext;
  text-decoration:none'>ctrs@ctrs.fr </span></a></span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=FR>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:3.25in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=FR>Luxembourg/Luxemburg</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=FR>Laboratoires CTRS</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=FR>T&eacute;l/Tel:
  +352 278 62 329</span></p>
  <p class=MsoNormal style='margin-right:1.7pt;line-height:normal'><span
  lang=FR><a href="mailto:ctrs@ctrs.fr"><span style='color:windowtext;
  text-decoration:none'>ctrs@ctrs.fr </span></a></span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.3pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=FR>&#268;esk&aacute;
  republika</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=FR>Laboratoires CTRS</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=FR>Tel.: </span><span
  lang=FR>+ 33 (0)1&nbsp;70&nbsp;76&nbsp;06&nbsp;37</span></p>
  <p class=MsoNormal style='margin-right:1.7pt;line-height:normal'><span
  lang=FR><a href="mailto:ctrs@ctrs.fr"><span style='color:windowtext;
  text-decoration:none'>ctrs@ctrs.fr </span></a></span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:3.25in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Magyarorsz&aacute;g</span></b></p>
  <p class=MsoNormal style='line-height:normal'>Medis Hungary Kft</p>
  <p class=MsoNormal style='line-height:normal'>Tel: +36 (2) 380 1028</p>
  <p class=MsoNormal style='line-height:normal'><a href="mailto:info@medis.hu"><span
  style='color:windowtext;text-decoration:none'>info@medis.hu</span></a> </p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.3pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=DE>Danmark</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=DE>Immedica Pharma
  AB </span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=DE>Tlf: +46 (0)8 533
  39 500 </span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=DE><a
  href="https://microsofteur-my.sharepoint.com/personal/muhamayu_microsoft_com/Documents/Projects/EMA/data/word2html/first_batch/word_for_original_pdfs/Spike%20Sample%20PIs%20in%20Word/info@immedica.com"><span
  style='color:windowtext;text-decoration:none'>info@immedica.com</span></a></span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:3.25in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=FR>Malta</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=FR>Laboratoires CTRS</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=FR>Tel: </span><span
  lang=FR>+356 2776 1358</span></p>
  <p class=MsoNormal style='margin-right:1.7pt;line-height:normal'><span
  lang=FR><a href="mailto:ctrs@ctrs.fr"><span style='color:windowtext;
  text-decoration:none'>ctrs@ctrs.fr </span></a></span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=FR>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.3pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=FR>Deutschland</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=FR>Laboratoires CTRS</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=FR>Tel: +49
  (0)3022153008</span></p>
  <p class=MsoNormal style='margin-right:1.7pt;line-height:normal'><span
  lang=FR><a href="mailto:ctrs@ctrs.fr"><span style='color:windowtext;
  text-decoration:none'>ctrs@ctrs.fr </span></a></span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=FR>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:3.25in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=FR>Nederland</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=FR>Laboratoires CTRS</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=FR>Tel: +31 (0)2 070
  38 155</span></p>
  <p class=MsoNormal style='margin-right:1.7pt;line-height:normal'><span
  lang=FR><a href="mailto:ctrs@ctrs.fr"><span style='color:windowtext;
  text-decoration:none'>ctrs@ctrs.fr </span></a></span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=FR>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.3pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=IT>Eesti</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=IT>Immedica Pharma
  AB </span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=IT>Tel/Puh: +46 (0)8
  533 39 500 </span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=DE><a
  href="mailto:info@immedica.com"><span style='color:windowtext;text-decoration:
  none'>info@immedica.com</span></a> </span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:3.25in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=IT>Norge</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=IT>Immedica Pharma
  AB</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=IT>Tel/Puh: +46 (0)8
  533 39 500 </span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=DE><a
  href="mailto:info@immedica.com"><span style='color:windowtext;text-decoration:
  none'>info@immedica.com</span></a> </span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.3pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&#917;&#955;&#955;&#940;&#948;&#945;</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=FR>Laboratoires CTRS</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=FR>Tel: </span><span
  lang=FR>+ 33 (0)1&nbsp;70&nbsp;76&nbsp;06&nbsp;37</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=FR><a
  href="mailto:ctrs@ctrs.fr"><span style='color:windowtext;text-decoration:
  none'>ctrs@ctrs.fr</span></a> </span></p>
  </td>
  <td width=312 valign=top style='width:3.25in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=FR>&Ouml;sterreich</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=FR>Laboratoires CTRS</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=FR>Tel: +43 (0)7 208
  16 847</span></p>
  <p class=MsoNormal style='margin-right:1.7pt;line-height:normal'><span
  lang=FR><a href="mailto:ctrs@ctrs.fr"><span style='color:windowtext;
  text-decoration:none'>ctrs@ctrs.fr </span></a></span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=FR>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 colspan=2 valign=top style='width:3.25in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=ES>Espa&ntilde;a</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=FR>Laboratoires CTRS</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=FR>Tel: </span><span
  lang=FR>+ (34) 914 146 613</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=FR><a
  href="mailto:ctrs@ctrs.fr"><span style='color:windowtext;text-decoration:
  none'>ctrs@ctrs.fr </span></a></span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=FR>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:3.25in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=FR>Polska</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=FR>Laboratoires CTRS</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=FR>Tel.: </span><span
  lang=FR>+ 33 (0)1&nbsp;70&nbsp;76&nbsp;06&nbsp;37</span></p>
  <p class=MsoNormal style='margin-right:1.7pt;line-height:normal'><span
  lang=FR><a href="mailto:ctrs@ctrs.fr"><span style='color:windowtext;
  text-decoration:none'>ctrs@ctrs.fr </span></a></span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=FR>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 colspan=2 valign=top style='width:3.25in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=FR>France</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=FR>Laboratoires CTRS</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=FR>T&eacute;l: </span><span
  lang=FR>+ 33 (0)1&nbsp;70&nbsp;76&nbsp;06&nbsp;37</span></p>
  <p class=MsoNormal style='margin-right:1.7pt;line-height:normal'><span
  lang=FR><a href="mailto:ctrs@ctrs.fr"><span style='color:windowtext;
  text-decoration:none'>ctrs@ctrs.fr </span></a></span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=FR><b>&nbsp;</b></span></p>
  </td>
  <td width=312 valign=top style='width:3.25in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=FR>Portugal</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=FR>Laboratoires CTRS</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=FR>Tel: </span><span
  lang=FR>+ 33 (0)1&nbsp;70&nbsp;76&nbsp;06&nbsp;37</span></p>
  <p class=MsoNormal style='margin-right:1.7pt;line-height:normal'><span
  lang=FR><a href="mailto:ctrs@ctrs.fr"><span style='color:windowtext;
  text-decoration:none'>ctrs@ctrs.fr </span></a></span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=PT>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 colspan=2 valign=top style='width:3.25in;padding:0in 5.4pt 0in 5.4pt'><span
  lang=SV style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
  clear=all style='page-break-before:always'>
  </span>
  <p class=MsoNormal style='line-height:normal'><b><span lang=SV>Hrvatska</span></b></p>
  <p class=MsoNormal><span lang=SV>Medis Adria d.o.o.</span></p>
  <p class=MsoNormal>Tel: +385 (1) 230 3446</p>
  <p class=MsoNormal><a href="mailto:info@medisadria.hr"><span
  style='color:windowtext;text-decoration:none'>info@medisadria.hr</span></a> </p>
  <p class=MsoNormal style='margin-right:1.7pt;line-height:normal'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:3.25in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=FR>Rom&acirc;nia</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=FR>Laboratoires CTRS</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=FR>Tel: </span><span
  lang=FR>+ 33 (0)1&nbsp;70&nbsp;76&nbsp;06&nbsp;37</span></p>
  <p class=MsoNormal style='margin-right:1.7pt;line-height:normal'><span
  lang=FR><a href="mailto:ctrs@ctrs.fr"><span style='color:windowtext;
  text-decoration:none'>ctrs@ctrs.fr </span></a></span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=FR>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 colspan=2 valign=top style='width:3.25in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=FR>Ireland</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=FR>Laboratoires CTRS</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=FR>Tel: +353 (0)1
  695 00 63</span></p>
  <p class=MsoNormal style='margin-right:1.7pt;line-height:normal'><span
  lang=EN-GB><a href="mailto:ctrs@ctrs.fr"><span lang=FR style='color:windowtext;
  text-decoration:none'>ctrs@ctrs.fr </span></a></span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=FR>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:3.25in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=NO-NYN>Slovenija</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=NO-NYN>Medis d.o.o.</span></p>
  <p class=MsoNormal style='line-height:normal'>Tel: +386 (1) 589 6900</p>
  <p class=MsoNormal style='line-height:normal'><a href="mailto:info@medis.si"><span
  style='color:windowtext;text-decoration:none'>info@medis.si</span></a> </p>
  <p class=MsoNormal style='line-height:normal'><b><span lang=FR>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 colspan=2 valign=top style='width:3.25in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&Iacute;sland</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Immedica
  Pharma AB</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=DE>S&iacute;mi: + 46
  (0)8 533 39&nbsp;500</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=DE><a
  href="mailto:info@immedica.com"><span style='color:windowtext;text-decoration:
  none'>info@immedica.com</span></a></span></p>
  </td>
  <td width=312 valign=top style='width:3.25in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=FR>Slovensk&aacute;
  republika</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=FR>Laboratoires CTRS</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=FR>Tel: </span><span
  lang=FR>+ 33 (0)1&nbsp;70&nbsp;76&nbsp;06&nbsp;37</span></p>
  <p class=MsoNormal style='margin-right:1.7pt;line-height:normal'><span
  lang=FR><a href="mailto:ctrs@ctrs.fr"><span style='color:windowtext;
  text-decoration:none'>ctrs@ctrs.fr </span></a></span></p>
  <p class=MsoNormal style='line-height:normal'><b><span lang=PT>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 colspan=2 valign=top style='width:3.25in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=FR>Italia</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=FR>Laboratoires CTRS</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=FR>Tel: +39 (</span><span
  lang=FR>0)687 501302</span></p>
  <p class=MsoNormal style='margin-right:1.7pt;line-height:normal'><span
  lang=FR><a href="mailto:ctrs@ctrs.fr"><span style='color:windowtext;
  text-decoration:none'>ctrs@ctrs.fr </span></a></span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=FR><b>&nbsp;</b></span></p>
  </td>
  <td width=312 valign=top style='width:3.25in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=IT>Suomi/Finland</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=IT>Immedica Pharma
  AB</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=IT>Tel/Puh: +46 (0)8
  533 39 500 </span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=DE><a
  href="mailto:info@immedica.com"><span style='color:windowtext;text-decoration:
  none'>info@immedica.com</span></a></span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 colspan=2 valign=top style='width:3.25in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&#922;&#973;&#960;&#961;&#959;&#962;</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=FR>Laboratoires CTRS</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=FR>Tel: </span><span
  lang=FR>+ 33 (0)1&nbsp;70&nbsp;76&nbsp;06&nbsp;37</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=FR><a
  href="mailto:ctrs@ctrs.fr"><span style='color:windowtext;text-decoration:
  none'>ctrs@ctrs.fr</span></a></span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=FR><b>&nbsp;</b></span></p>
  </td>
  <td width=312 valign=top style='width:3.25in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=DE>Sverige</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Immedica
  Pharma AB</span><span lang=DE> </span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=DE>Tel: +46 (0)8 533
  39 500 </span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=DE><a
  href="mailto:info@immedica.com"><span style='color:windowtext;text-decoration:
  none'>info@immedica.com</span></a></span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 colspan=2 valign=top style='width:3.25in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=IT>Latvija</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=IT>Immedica Pharma
  AB</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=IT>Tel: +46 (0)8 533
  39 500 </span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=DE><a
  href="mailto:info@immedica.com"><span style='color:windowtext;text-decoration:
  none'>info@immedica.com</span></a></span></p>
  </td>
  <td width=312 valign=top style='width:3.25in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>United
  Kingdom</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Laboratoires
  CTRS</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Tel: +44 (0)3
  301 002 375</span></p>
  <p class=MsoNormal style='margin-right:1.7pt;line-height:normal'><span
  lang=FR><a href="mailto:ctrs@ctrs.fr"><span style='color:windowtext;
  text-decoration:none'>ctrs@ctrs.fr&nbsp; </span></a>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 colspan=2 valign=top style='width:3.25in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=FR>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:3.25in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=FR>&nbsp;</span></p>
  </td>
 </tr>
 <tr height=0>
  <td width=2 style='border:none'></td>
  <td width=310 style='border:none'></td>
  <td width=312 style='border:none'></td>
 </tr>
</table>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>This leaflet was last </span><span lang=EN-GB>revised </span></b><b><span
lang=EN-GB>in</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><i><span
lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>This medicine has been authorised under &#8220;Exceptional
Circumstances&#8221;.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>This means that because of the rarity of this disease and for
ethical reasons it has been impossible to get complete information on this
medicine.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>The European Medicines Agency will review any new information on the
medicine every year and this leaflet will be updated as necessary.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>Other sources of information</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Detailed information on this medicine is available on the European
Medicines Agency web site: <a href="http://www.ema.europa.eu/">http://www.ema.europa.eu</a>/.
There are also links to other websites about rare diseases and treatments.</span></p>

</div>

</body>

</html>
